tiprankstipranks
Advertisement
Advertisement

Healios Proposes New Board Slate Ahead of March Shareholders Meeting

Story Highlights
  • Healios K.K. has nominated five directors, including three outsiders, for election at its March 2026 shareholders meeting.
  • The company also named an alternate director, reinforcing governance stability as it advances its regenerative medicine growth strategy.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Healios Proposes New Board Slate Ahead of March Shareholders Meeting

Claim 55% Off TipRanks

Healios KK ( (JP:4593) ) just unveiled an update.

Healios K.K. has nominated five candidates for its Board of Directors, including Chairman Hardy TS Kagimoto as director, current CFO Richard Kincaid as director, and three outside directors, Seigo Kashii, Yuko Yogo, and Glenn Gormley. The nominations, decided by the Board following the Nomination Committee’s recommendations, will be submitted for approval at the company’s 15th Ordinary General Meeting of Shareholders on March 25, 2026.

The company has also proposed Kouichi Tamura as an alternate director to ensure the board maintains the legally required number of members if vacancies arise. The refreshed board slate, with a mix of internal leadership and multiple outside directors, underscores Healios’ focus on independent oversight and governance stability as it advances its regenerative medicine initiatives and navigates its growth phase on the TSE Growth Market.

The most recent analyst rating on (JP:4593) stock is a Hold with a Yen367.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.

More about Healios KK

Healios K.K. is a Japan-based biotech company listed on the TSE Growth Market under code 4593. The company focuses on regenerative medicine and cell therapy, developing advanced treatments that leverage stem cell technologies for serious diseases, positioning it within the high-growth life sciences and healthcare innovation sector.

Led by Chairman and CEO Hardy TS Kagimoto, Healios targets both domestic and global markets for next-generation medical solutions. Its strategy emphasizes clinical development, regulatory progress, and partnerships to commercialize novel therapies, aiming to strengthen its competitive position in the regenerative medicine field.

Average Trading Volume: 4,048,983

Technical Sentiment Signal: Sell

Current Market Cap: Yen50.22B

Find detailed analytics on 4593 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1